Table 2.

Comprehensive databases accessible for AKI research (Core A)

Database	Data Source	Data Content
International ICU AKI Registry	33 centers worldwide	Comorbidities, risk factors for AKI, clinical and laboratory data, fluid balance status, severity of illness scores, dialysis requirements and outcomes through hospital discharge. Currently, 17,444 patients have been screened and 3,179 patients are enrolled.
Drug-Induced Renal Injury Consortium	42 centers worldwide	634 patients (adult, n = 493; pediatric, n = 141) with drug-induced kidney disease. Blood, urine, and DNA samples have been collected as well as the clinical course of injury and outcomes up to 90 days post event.
Global Snapshot of AKI	International Society of Nephrology 0by25 project	Phenotypic information on 4,018 patients (adult, n = 3,664; pediatric, n = 354) enrolled from 289 centers in 92 countries. Presenting symptoms, risk factors, course, and outcome over 7 days of patients with AKI.
UAB and UCSD Clinical Data Warehouse from EHR	UCSD Epic with Clarity and UAB Cerner Datasets	Clinical laboratory, medication, and administrative data for outpatient and inpatient encounters at UAB and UCSD.
UC Accrual to Clinical Trials	Administrative and EHR data from 5 UC medical centers	Detailed data on demographics, diagnosis, procedures, laboratory, medication, and vital signs.
COVID-19 Kidney Disease Global Study	Data from 74 centers across 25 countries	Clinical data on course and outcomes of patients with COVID-19 with AKI, chronic kidney disease, end-stage kidney disease, and transplant (>3,000 patients as of March 1, 2021).

AKI, acute kidney injury; ICU, intensive care unit; UAB, University Of Alabama at Birmingham; UCSD, University of California-San Diego; EHR, electronic health records; UC, University of California.